



September 1, 2017

## Intercept to Present at Upcoming Conferences

NEW YORK, Sept. 01, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the following investor conferences:

- | Baird 2017 Global Healthcare Conference on September 6, 2017 at 1:25 p.m. Eastern Time
- | Morgan Stanley 15<sup>th</sup> Annual Global Healthcare Conference on September 12, 2017 at 11:45 a.m. Eastern Time

Webcast information for these events will be available on the Investors page of Intercept's website at <http://ir.interceptpharma.com>. Archived webcasts will be available on Intercept's website for approximately two weeks.

### **About Intercept**

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada.

### CONTACT:

For more information about Intercept Pharmaceuticals, please contact:

Intercept Pharmaceuticals:

Mark Vignola

+1-646-747-1000

[investors@interceptpharma.com](mailto:investors@interceptpharma.com)

Media inquiries: [media@interceptpharma.com](mailto:media@interceptpharma.com)

Investor inquiries: [investors@interceptpharma.com](mailto:investors@interceptpharma.com)